View more job listings or post a job
Genentech Scientist, DMPK
Pliant Therapeutics, Inc. Associate Director/ Director, Formulation Development
AbVision Inc. Research Scientist (Immunology/Cell Biology, all levels available)
Regulus Therapeutics Senior Research Associate/Scientist, Drug Metabolism and Pharmacokinetics
Aligos Therapeutics Principal Research Scientist, DMPK
PPD, Inc. Senior Scientist - Quality Control - HPLC - Dissolution - Method Validation
Aligos Therapeutics Director DMPK
Genentech Senior Scientific Researcher, DMPK
Genentech Scientist/Sr. Scientist Small Molecule - In Vitro DMPK
Post a job


Biotransformation and Disposition of Larger Molecules: Peptides, Nucleotides, Proteins, mAbs, and ADCs

Speakers: Donglu Zhang (Genentech), Mark Cancilla (Merck), Jing Li (Alnylam Pharmaceuticals), Srikanth Kotapat (Bristol-Myers Squibb), Mei Han (Amgen), Fang Xie (Amgen), Ben Shen (Genentech), Divya Samineni (Genentech), Dian Su (Genentech)
Organizers: Dian Su (Genentech)
Date: 2019-09-13
Time: 8:45-17:00 Pacific Time
Registration fee (USD): Regular: $195; Academic: $125; For unemployed or students: $30; For major-sponsor rep (incl lunch): $0; For vendor-show rep: $35
Location: SF Bay Area: Foster City Crowne Plaza
Major Sponsor:
Vendor show vendors registered to date: (2)MicroConstants; Q2 Solutions
Registration deadline:2019-09-11  (it will close sooner if the seating cap is reached)

About the Topic

​Biotransformation of small molecules is intensively investigated during drug discovery and development stages. In contrast, biotransformation of larger molecules such as antibodies, proteins, antibody-drug conjugates, peptides and nucleotides has been less emphasized. In the last decade, there have been increasing interests and expertise in understanding of larger molecule biotransformation and disposition. This workshop will cover this topic for diverse therapeutics and provide an opportunity for the community to discuss the technical aspect, role and impact of biotransformation for development of larger molecule therapeutics.

Key topics:

  • Introduction to Disposition and Biotransformations of Larger Molecules 
  • Biotransformation and Trafficking of Peptide Therapeutics
  • Biotransforamtionand biodistribution of Oligonucleotide Therapeutics 
  • Biotransformation of Antibody Therapeutics
  • Biotransformation of Next-generation ADCs
  • Tissue Disposition of Protein and Antibody Therapeutics

2019-07-26, Generating Efficacious Enzyme Therapeutics based on Knowledge Learned From Biocatalytic Pharmaceutical Manufacture
2019-10-03, Small-Molecule Bioanalytical Method Validation & Regulated Bioanalysis: Fundamentals, the New FDA Guidance and Regulatory Trends
2019-10-18, Physiologically Based Pharmacokinetic (PBPK) Modeling: Fundamentals, Regulatory Guidance & Applications
2019-11-12, Antibody Drug Discovery and Development: Hit Generation, Engineering, Cell-line Development, IND enabling studies, and Biosimilars
2019-12-10, In vitro Diagnostics and Precision Medicine
2020-02-11, Drug-Device Combination
©Pharmaceutical & BioScience Society, International; Last Modified: 6/26/2019; Visited: 1015; Admin Logon
Ads (in random order)
Submit a Text Ad
($250 for 2 months)

Pacific BioLabs CRO in Bay Area - PK, toxicology, biocompatibility, analytical chemistry, immunogenicity, biomarker analysis, stability studies, sterility, endotoxin
Hypha Discovery mg-g scale synthesis/purification of CYP/non-CYP metabolites including glucuronides. Plus NEW PolyCYPs kits for in-house synthesis of CYP metabolites.
Immunomind Scientific Consulting - Protocol Development, Data Analysis, Lab Guidance, Tech Transfer - Meeting your project goals at a moment's notice.
Submit a Text Ad